SEC Form 4 · accession 0001209191-15-037170
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Terrence C Kearney
Director
Period of report
Apr 27, 2015
Accepted (ET)
Apr 29, 2015 · 8:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 27, 2015 | M | 28,125 | $56.99 | A | 28,125 | D | |
| Common Stock | Apr 27, 2015 | M | 20,000 | $53.85 | A | 48,125 | D | |
| Common Stock | Apr 27, 2015 | M | 20,000 | $59.55 | A | 68,125 | D | |
| Common StockF2,F3 | Apr 27, 2015 | S | 26,593 | $127.50 | D | 41,532 | D | |
| Common StockF3,F4 | Apr 27, 2015 | S | 16,295 | $128.12 | D | 25,237 | D | |
| Common StockF3,F5 | Apr 27, 2015 | S | 4,500 | $129.94 | D | 20,737 | D | |
| Common StockF3,F6 | Apr 27, 2015 | S | 8,800 | $130.58 | D | 11,937 | D | |
| Common StockF3,F7 | Apr 27, 2015 | S | 3,969 | $131.76 | D | 7,968 | D | |
| Common StockF3,F8 | Apr 27, 2015 | S | 5,668 | $132.82 | D | 2,300 | D | |
| Common StockF3,F9 | Apr 27, 2015 | S | 2,300 | $133.63 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F10 | $56.99 | Apr 27, 2015 | M | 28,125 | D | — | May 16, 2021 | Common Stock | 28,125 | 1,875 | D |
| Stock Option (right to buy)F11 | $53.85 | Apr 27, 2015 | M | 20,000 | D | — | May 31, 2021 | Common Stock | 20,000 | 0 | D |
| Stock Option (right to buy)F11 | $59.55 | Apr 27, 2015 | M | 20,000 | D | — | May 31, 2022 | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1.
- F10The option vests in 16 quarterly installments from 05/17/2011.
- F11Fully vested.
- F2Open market sales reported on this line occurred at a weighted average price of $127.50 (range $126.87 to $127.86).
- F3Mr. Kearney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $128.12 (range $127.87 to $128.83).
- F5Open market sales reported on this line occurred at a weighted average price of $129.94 (range $129.16 to $130.15).
- F6Open market sales reported on this line occurred at a weighted average price of $130.58 (range $130.16 to $131.14).
- F7Open market sales reported on this line occurred at a weighted average price of $131.76 (range $131.25 to $132.20).
- F8Open market sales reported on this line occurred at a weighted average price of $132.82 (range $132.32 to $133.30).
- F9Open market sales reported on this line occurred at a weighted average price of $133.63 (range $133.36 to $134.09).